Research

Hormonal

In humanized GLP-1 receptor mice, small-molecule GLP-1 receptor agonists (e.g., orforglipron) produce metabolic effects (weight loss, glucose tolerance) comparable to peptide-based agonists (e.g., semaglutide).

Small-molecule GLP-1 drugs can work as well as peptide drugs in terms of metabolic effects, provided they bind to the correct receptor. This humanized mouse model confirms that oral small-molecule options have the potential to match the efficacy of injectable peptides.

GoodSupportsHIGH confidence
Semaglutide (30 nmol/kg) and orforglipron (3.0 mg/kg) exhibited comparable efficacy in stimulating insulin secretion during an IPGTT... both compounds showed similar capacity to suppress post-prandial glucose excursions during an OGTT.
Nina Sonne et al. · EBioMedicine · 2026

Why this rating

Robust in vivo data across multiple metabolic endpoints (glucose tolerance, body weight, food intake) in a validated animal model.

Source

Generation and characterisation of a humanised GLP-1 receptor mouse model for translational drug development

Nina Sonne et al. · EBioMedicine · 2026

DOI 10.1016/j.ebiom.2026.106121

mechanism_onlyCited 3×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →